Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study

MLA

Suey-Haur Lee, et al. “Comparison of Afatinib and Erlotinib Combined with Bevacizumab in Untreated Stage IIIB/IV Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma Patients: A Multicenter Clinical Analysis Study.” Therapeutic Advances in Medical Oncology, vol. 14, July 2022. EBSCOhost, https://doi.org/10.1177/17588359221113278.

APA

Suey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Shih-Hong Li, Yueh-Fu Fang, Chih-Hung Chen, Scott Chih-Hsi Kuo, Chin-Chou Wang, Cheng-Ta Yang, & Ping-Chih Hsu. (2022). Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study. Therapeutic Advances in Medical Oncology, 14. https://doi.org/10.1177/17588359221113278

Chicago

Suey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Shih-Hong Li, et al. 2022. “Comparison of Afatinib and Erlotinib Combined with Bevacizumab in Untreated Stage IIIB/IV Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma Patients: A Multicenter Clinical Analysis Study.” Therapeutic Advances in Medical Oncology 14 (July). doi:10.1177/17588359221113278.